Trial: 202010169

CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): DoseEscalation Study to Assess Safety and Tolerability

Phase

Early Phase I

Principal Investigator

Kim, Seung Kwon

Disease Site

Liver

Learn more about this study at: clinicaltrials.gov